Core Framework & Diagram Great Scientists in Immunology History
July 24, 20261 Min Read Where Is Immunology Headed?
July 24, 2026They saw what others couldn't see
—— Twelve people who shaped modern immunology — and the stories behind them.
I. Metchnikoff: the man who saw cellular immunity in isolation
Élie Metchnikoff's story is a classic case in scientific history of 'making the right discovery in the wrong place, at the wrong time.' In 1882, observing starfish larvae in Messina, Sicily, Metchnikoff inserted a rose thorn into a larva's body and the next day saw large numbers of moving cells gathering around the thorn, trying to engulf it. He immediately realized: this was not random cell accumulation but active defensive behavior — cells were attacking a foreign invader. He named these cells 'phagocytes' and proposed cellular immunity theory: immune protection's essence is cells' phagocytosis and killing, not some mysterious chemical in the blood. This idea was almost isolated at the time. The mainstream German medical world (led by Koch and Ehrlich) firmly maintained immunity was 'humoral' (chemical substances in serum), viewing Metchnikoff's cellular theory with widespread skepticism or even mockery. Metchnikoff was Russian, working at the Pasteur Institute in France, naturally positioned in opposition to the German mainstream. He persisted for a full twenty years against various criticism and doubt.
In 1908, Metchnikoff shared the Nobel Prize with his 'adversary' Paul Ehrlich, representing the humoral immunity camp. In his acceptance remarks, Metchnikoff said: 'Perhaps our debate was beneficial — it made each side examine their own theory more carefully.' This is a scientist showing rare generosity after a controversy settled. Metchnikoff's later years had another noteworthy aspect: he had an almost obsessive interest in 'longevity,' believing gut microbiota (particularly what he called 'lactic acid bacteria') was the key to determining lifespan, advocating consuming large amounts of yogurt to supplement 'beneficial bacteria.' This idea was considered eccentric in his era — but one hundred twenty years later, it has become an active research field: gut microbiota's relationship to immune function and lifespan is one of modern immunology's frontiers.
2. Karikó: twenty years of persistence saved hundreds of millions
Katalin Karikó's story is one of the most moving narratives about persistence in modern scientific history. In 1985, Karikó came from Hungary to America and began researching mRNA therapy's possibilities at the University of Pennsylvania. She believed that directly injecting therapeutic protein-encoding mRNA into human cells — letting cells synthesize needed proteins themselves — would open a completely new treatment modality. In the following twenty years, Karikó's experience was a series of setbacks: almost every funding application she submitted was rejected; the university canceled her tenure, demoting her with corresponding pay reduction; she was diagnosed with breast cancer; her husband, returning from a business trip to America, was stranded in Hungary for six months due to visa problems. But she didn't give up. In 1998 she began collaborating with Drew Weissman, focusing on one core question: why does the body's innate immune system attack injected mRNA? They spent seven years finding the answer: uridine (U) in natural mRNA is TLR7's recognition target, triggering innate immune activation. When they replaced ordinary uridine with chemically modified nucleosides (N1-methylpseudouridine, m1Ψ), mRNA's immunogenicity greatly decreased while protein translation efficiency improved. This finding was published in 2005, generating almost no attention at the time.
In 2020, COVID-19 broke out and BioNTech and Moderna respectively rapidly applied Karikó and Weissman's nucleoside modification technology to COVID mRNA vaccines — these two vaccines ultimately administered to over three billion people, the fastest-deployed and most widely adopted vaccines in human history. In 2023, Karikó and Weissman jointly received the Nobel Prize. At the award ceremony, Karikó said: 'I never thought of giving up, because my passion for science itself never changed.'
3. Ralph Steinman: Nobel Prize three days after death
Ralph Steinman's story has a uniquely tragic ending in immunology history, and an unforgettable human footnote. In 1973, Steinman at Rockefeller University in New York discovered dendritic cells (DC). Previously, immunologists knew macrophages could engulf and present antigens, but whether specialized presentation cells existed in the antigen presentation process was unclear. Under the microscope, Steinman observed a type of cell with special morphology — having numerous tree-like protrusions (dendrites), thus naming them dendritic cells — and through a series of experiments proved these cells were the most potent antigen-presenting cells for activating naive T cells, crucial for initiating adaptive immune responses. This discovery initially met skepticism too. Dendritic cells are extremely rare in blood and tissue (under 0.1% of peripheral blood mononuclear cells), making isolation and purification extremely difficult; many labs couldn't replicate Steinman's results. He spent nearly ten years, in the face of sustained doubts, gradually building the evidence base establishing DCs as immune response initiators.
In 2007, Steinman was diagnosed with pancreatic cancer — with a median survival of only six months. He decided to run an experiment using his own body: using dendritic cell vaccines (personalized vaccines prepared by loading tumor antigens onto autologous DCs) combined with other experimental therapies for self-treatment. He survived four full years after diagnosis, far exceeding expectations — he believed DC vaccines may have played a role, though couldn't confirm. On October 3, 2011, Steinman died from pancreatic cancer at age 68. Just three days later on October 6, the Nobel Committee announced the 2011 Nobel Prize in Physiology or Medicine was awarded to Beutler, Hoffmann, and Steinman. Under Nobel rules, awards cannot be given posthumously — but after verifying Steinman had just died, the committee decided the award decision remained valid: they didn't know he had died when making the decision, so the award stood. This became the only case in Nobel Prize history of an award given to a deceased scientist, and one of the most moving moments in that award's history.
4. Charles Janeway: foreseeing the invisible truth
Charles Janeway Jr.'s name is almost unknown to the general public, but in immunology he is universally recognized as the founder of modern innate immunity theory's theoretical basis. His most important contribution was a prediction made in a 1989 lecture and subsequent paper — completely unverifiable with then-available technology, but ultimately proven completely correct. In 1989, Janeway at a Cold Spring Harbor Laboratory lecture proposed: the innate immune system must have specific receptors (which he called 'pattern recognition receptors,' PRR) specifically recognizing pathogen conserved molecular features (which he called 'pathogen-associated molecular patterns,' PAMP). This prediction was considered speculative at the time — because no known molecule then fit the PRR characteristics he described. His colleagues listened politely but most didn't take it seriously. Janeway died in 2003 at age 60, unable to see his prediction completely validated. In 1996, Jules Hoffmann discovered Toll receptor's role in immune defense in Drosophila; in 1997, Bruce Beutler discovered the corresponding TLR4 receptor in mammals, proving it recognized bacterial endotoxin (LPS) — precisely the classic case of PRR recognizing PAMP that Janeway predicted. Hoffmann and Beutler shared the 2011 Nobel with Steinman, while Janeway, already deceased, couldn't share that honor. The immunology community universally believes that if Janeway had lived longer, he almost certainly would have been in Stockholm for that award.
5. Their shared characteristics: the ability to see and the power to persist
Reviewing these twelve immunology founders' stories, a few impressively consistent qualities stand out. First, they all had the courage to make bold hypotheses on limited evidence — Janeway predicted PRR when no known molecule supported it; Karikó persisted in mRNA research for twenty years without any external recognition; Metchnikoff maintained cellular immunity in opposition to the entire German mainstream. Second, their breakthroughs often came from high sensitivity to 'anomalous observations' — Pasteur noticed old bacterial cultures had lost virulence; Metchnikoff noticed cells gathering around a thorn; Steinman noticed morphologically unique tree-like cells under the microscope. This sensitivity isn't a technique but a quality: staying curious about the unexpected rather than filing it under 'experimental error.' Third, almost every important immunologist faced real opposition, mockery, funding cuts, or academic exclusion — but their shared choice was to keep doing experiments, letting data speak, rather than yielding to opinion. This persistence, in today's academic environment demanding rapid publication and rapid output, is becoming increasingly rare and increasingly precious.
Frequently Asked Questions